H.C. Wainwright lowered the firm’s price target on Clearside Biomedical (CLSD) to $5 from $6 and keeps a Buy rating on the shares following the Q1 report. The firm’s estimated market value of the company remains unchanged, but the projected shares outstanding have increased.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical Reports Q1 2025 Financial Progress
- Clearside Biomedical: Undervalued Opportunity with Strategic Partnerships and Promising CLS-AX Advancements
- Clearside Biomedical reports Q1 EPS (11c), consensus (11c)
- Clearside Biomedical announces six presentations related to CLS-AX
- Buy Rating for Clearside Biomedical Backed by Promising Trial Results and FDA Alignment
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue